Skip to content
TrialScanner

NCT01652469

Testing of Drugs Erlotinib and Docetaxel in Lung Cancer Patients Classified Regarding Their Outlook Using VeriStrat®.

Phase 3CompletedBDSXCollaborator

Registry record

Lead sponsor
ETOP IBCSG Partners Foundation
Conditions
Carcinoma, Non-Small-Cell Lung
Primary completion
Dec 2015Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT01652469 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT01652469: Testing of Drugs Erlotinib... | TrialScanner